Put the two literatures next to each other and the asymmetry is hard to miss.
| Men | Women | |
|---|---|---|
| Landmark trial | TRAVERSE — 5,204 participants, designed around major adverse cardiac events[1] | — |
| Best available synthesis | Endocrine Society clinical practice guideline[2] | Global Consensus Position Statement, 2019[3] |
| Randomised evidence | Multiple dedicated sub-studies: fractures,[4] sexual function,[5] mood[6] | Systematic review and meta-analysis of the RCT data that exists[7] |
| Diagnostic threshold | Symptoms plus consistently low confirmed morning levels[2] | No established threshold[3] |
Nothing in that table follows from biology. It follows from which questions got funded.
Why the consensus statement's date matters
The Global Consensus Position Statement was published in 2019.[3] Testosterone has been clinically available since 1935.[8]
Eighty-four years between a hormone entering clinical use and the first international consensus on using it in half the population. That is the gap in a single comparison.
What the gap costs in practice
No diagnostic threshold. Clinicians work without the tool their male-side colleagues have.[3]
Assay validity problems. Many assays were built for male concentrations, and female levels sit far lower.
Products designed for men. Which forces improvisation in dosing — see dosing women differently.
Regulatory limbo. Without the trial base that supports approvals, provision falls into off-label and compounded territory, which is the subject of the ISSWSH and FDA standoff.
What has been done well
Worth crediting, because the response to a thin evidence base was not to fill it with assertion.
The 2019 systematic review pooled the randomised controlled trial data specifically — trials, not observational impressions.[7] The consensus statement was built on that and endorsed internationally.[3] Faced with limited evidence, the field produced a careful synthesis and stated the limits.
That is the right response, and it is a marked contrast with the male field's own history, where the gap between a plausible mechanism and an untested intervention produced seventeen years of rejuvenation surgery.[10]
Frequently asked questions
Why is there so much less research? Funding and historical priority rather than biological difference. The consensus statement arriving in 2019 is the clearest marker.[3]
Does that mean treatment is unsafe for women? No. It means the evidence base is narrower and the supported indications correspondingly narrower.[3][7]
Is this changing? The 2019 statement and its underlying meta-analysis represent real progress. The comparison in the table above is still the current position.
Next in this series
A narrow evidence base plus real clinical demand produces a regulatory standoff.
Continue with the ISSWSH and FDA standoff.
References
10 sources
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603 · PMID 31498871
- Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203–211. doi:10.1056/NEJMoa2308836 · PMID 38231621
- Pencina KM, Travison TG, Cunningham GR, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569–580. doi:10.1210/clinem/dgad484 · PMID 37589949
- Bhasin S, Seidman S, Travison TG, et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metab. 2024;109(7):1814–1826. doi:10.1210/clinem/dgae026 · PMID 38205962
- Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5 · PMID 31353194
- Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212. doi:10.1530/EJE-19-0071 · PMID 30959485
- Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737–2745. doi:10.1210/jc.2007-1972 · PMID 18270261
- Schultheiss D, Denil J, Jonas U. Rejuvenation in the early 20th century. Andrologia. 1997;29(6):351–355. doi:10.1111/j.1439-0272.1997.tb00329.x · PMID 9430441
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.